Dewilde, Sarah <br/><br/>
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.  [electronic resource] 

 -  Journal of medical economics  Feb 2014 
 - 111-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.3111/13696998.2013.873044  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bendamustine Hydrochloride<br/>Clinical Trials, Phase III as Topic<br/>Computer Simulation<br/>Cost-Benefit Analysis<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>England<br/>Female<br/>Humans<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Prednisone--administration & dosage<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Rituximab<br/>Vincristine--administration & dosage<br/>Wales